Showing 181 - 200 of 514 results
With the screening of the popular HBO series about Chernobyl, we asked our Nuclear Analysis team for their insights on key differences between the reactor in the TV series, a Generation II RBMK power reactor and ANSTO’s state of the art research reactor OPAL.
The radiography program focuses on the development of Neutron Capture Enhanced Particle Therapy (NCEPT) from initial preclinical work, to clinical trials and finally commercial translation and licencing.
The work of the group comprises Radioactivity Measurement Standards, Radioanalytical chemistry, Environmental Radioactivity Measurement Centre, Nuclear security science and Environmental monitoring.
The Think Science! event encourages students to engage with the Science Inquiry Skills process as outlined in the Australian National Curriculum.
Detailed data on ANSTO electricity use and CO2 emissions for FY2024 - FY2025
With a well-established portfolio of nuclear research and the operation of Australia's only nuclear reactor OPAL, ANSTO scientists conduct both fundamental and applied research on fuel for current, advanced, and future nuclear technology systems.
ANSTO operates a range of cobalt-60 gamma irradiators, providing the Australian community with a range of irradiation services for medical, health, industry, agriculture and research purposes.
ANSTO is dedicated to identifying opportunities for the application of knowledge and technology developed by the organisation for a wide range of industry applications.
ANSTO’s user office in Melbourne offers access to the Australian Synchrotron, a world-class research facility with over 4,000 user visits per year. ANSTO seeks collaboration and partnerships with research organisations, scientific users and commercial users.
Developed by ANSTO’s predecessor the Australian Atomic Energy Commission (known as the AAEC) in the late 1960s, the Technetium-99m Generator revolutionised nuclear medicine imaging in Australia by enabling imaging procedures to be performed not only in major capital cities but throughout regional and rural Australia.
Lutetium-177 used for advanced prostate cancer
ANSTO’s nuclear medicine processing and distribution facility assembles, loads, tests and distributes a range of nuclear medicine products, including Mo-99. The Mo-99 is dispensed into an ANSTO radiopharmaceutical Gentech® Generator where it decays to Tc-99m.
Australia and Sri Lanks signs new partnership to fight chronic kidney disease.
ANSTO Synroc® is constructing an Australian radioactive waste treatment facility for the by-products of Molybdenum-99 (Mo-99) production.
The role of trace elements as palaeoclimate proxies has been explored in ANSTO-led collaborative environmental research.